<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="and cause respiratory. The pneumonia caused by the novel coronavirus" exact="infection" post="is characterized by fever, cough, dyspnea, and ground-glass-type interstitial"/>
 <result pre="the National Administration of Traditional Chinese Medicine issued â€œGuidelines for" exact="diagnosis" post="and treatment of novel coronavirus pneumonia (Trial Version 5),â€�[1]"/>
 <result pre="Administration of Traditional Chinese Medicine issued â€œGuidelines for diagnosis and" exact="treatment" post="of novel coronavirus pneumonia (Trial Version 5),â€�[1] which advocated"/>
 <result pre="use of interferon-alpha (IFN-Î±), lopinavir/ritonavir (LPV/r) and ribavirin for the" exact="treatment" post="of COVID-19. Based on the previous reports and observational"/>
 <result pre="MERS patients.[2,3] These aforementioned therapeutic regimens are based on the" exact="treatment" post="experience during the SARS and MERS epidemics. However, there"/>
 <result pre="robust and reliable clinical evidence for the efficacy of these" exact="treatment" post="regimens for the treatment of COVID-19. In this present"/>
 <result pre="evidence for the efficacy of these treatment regimens for the" exact="treatment" post="of COVID-19. In this present study, we chose three"/>
 <result pre="effectiveness and safety of these different antiviral regimens for the" exact="treatment" post="of COVID-19. It should be noted that the recommended"/>
 <result pre="doses of the three prescribed drugs are based on the" exact="treatment" post="experience in past SARS and MERS clinical trials, and"/>
 <result pre="Patients will be blocked randomization individually to one of three" exact="treatment" post="arms by means of random computer-generated lists, with an"/>
 <result pre="Figure 1. Figure 1 Flow diagram of the study. The" exact="diagnosis" post="of mild to moderate COVID-19 will meet all of"/>
 <result pre="will meet all of the following criteria: (1) 2019-nCoV RNA" exact="detection" post="is positive in the upper respiratory tract via nasopharyngeal"/>
 <result pre="drugs to one arm of the study cohort for the" exact="treatment" post="of COVID-19. Some physicians do not recommend a combination"/>
 <result pre="more than three antiviral drugs in specific regimens for the" exact="treatment" post="of COVID-19 according to Version 6 of the clinical"/>
 <result pre="serological analysis of a recent Middle East respiratory syndrome coronavirus" exact="infection" post="case on a triple combination antiviral regimen. Int J"/>
 <result pre="J Antimicrob Agents2014; 44:528â€&quot;532. doi: 10.1016/j.ijantimicag.2014.07.026.25288266 4.ZhaoZZhangFXuMHuangKZhongWYinZet al.Description and clinical" exact="treatment" post="of an early outbreak of severe acute respiratory syndrome"/>
 <result pre="Med Microbiol2003; 52:715â€&quot;720. doi: 10.1099/jmm.0.05320-0.12867568 5.SoLYLauACYamLYCheungTMPoonEYungRWet al.Development of a standard" exact="treatment" post="protocol for severe acute respiratory syndrome. Lancet (North American"/>
</results>
